DEVICE AND PROCESS FOR ANALYSING GAS EFFECTS IN SAMPLES

    公开(公告)号:US20230408474A1

    公开(公告)日:2023-12-21

    申请号:US18250790

    申请日:2021-10-21

    IPC分类号: G01N33/00 G01J3/02

    摘要: The invention provides a device and a process for analysing the effect of a concentration of a gas on a sample, especially measurement of the gas concentration within a sample, and/or measurement of the effect of the absorption and/or desorption of a gas by the sample, using spectrophotometric detection of a gas-sensitive and optically detectable analyte of the sample while measuring the concentration of the gas in a gas composition that is continuously delivered to each sample well in order to contact the samples with a gas having a predetermined and/or measured concentration, respectively a pre-determined and/or measured partial pressure.

    Electrochemical cell
    2.
    发明授权

    公开(公告)号:US10369522B2

    公开(公告)日:2019-08-06

    申请号:US15107663

    申请日:2014-12-23

    摘要: Electrochemical cell array for the treatment of a sample via electro-(end-)osmotic flow, comprising (i) an electrode chamber, comprising a cathodic compartment (CC) and an anodic compartment (AC), (ii) a cathode (C), being arranged in the cathodic compartment (CC), (iii) an anode (A), being arranged in the anodic compartment (AC), (iv) an intermediate cathodic compartment (C1) (v) an intermediate anodic compartment (A1) (iv) a first selective membrane (M1) being arranged between said cathodic compartment (CC) and said first intermediate cathodic compartment (C1) (v) a second selective membrane (M2) being arranged between said anodic compartment (AC) and said first intermediate anodic compartment (A1) (vi) a treatment compartment (T) for the sample being arranged between said intermediate cathodic compartment (C1) and said intermediate anodic compartment (A1), further comprising a first separator membrane (S1) between said treatment compartment (T) and said intermediate cathodic compartment (C1) and a second separator membrane (S2) arranged between said treatment compartment (T) and said intermediate anodic compartment (A1).

    ELECTROCHEMICAL CELL
    3.
    发明申请

    公开(公告)号:US20160325230A1

    公开(公告)日:2016-11-10

    申请号:US15107663

    申请日:2014-12-23

    IPC分类号: B01D61/42 B01D61/46

    摘要: Electrochemical cell array for the treatment of a sample via electro-(end-)osmotic flow, comprising (i) an electrode chamber, comprising a cathodic compartment (CC) and an anodic compartment (AC), (ii) a cathode (C), being arranged in the cathodic compartment (CC), (iii) an anode (A), being arranged in the anodic compartment (AC), (iv) an intermediate cathodic compartment (C1) (v) an intermediate anodic compartment (A1) (iv) a first selective membrane (M1) being arranged between said cathodic compartment (CC) and said first intermediate cathodic compartment (C1) (v) a second selective membrane (M2) being arranged between said anodic compartment (AC) and said first intermediate anodic compartment (A1) (vi) a treatment compartment (T) for the sample being arranged between said intermediate cathodic compartment (C1) and said intermediate anodic compartment (A1), further comprising a first separator membrane (S1) between said treatment compartment (T) and said intermediate cathodic compartment (C1) and a second separator membrane (S2) arranged between said treatment compartment (T) and said intermediate anodic compartment (A1).

    MICRORNA-122 IN METABOLIC DISEASES
    10.
    发明申请

    公开(公告)号:US20190010547A1

    公开(公告)日:2019-01-10

    申请号:US15774001

    申请日:2016-11-04

    IPC分类号: C12Q1/6883

    摘要: The present invention relates to a predictive diagnostic method for identifying whether a patient will develop metabolic syndrome and/or type-2 diabetes in the future. In particular, the invention relates to a method for identifying a subject which has a risk for developing metabolic syndrome and/or type-2 diabetes, wherein the method comprises (a) analyzing (i.e. determining/measuring/quantifying) in a sample obtained from a test subject the amount of miR-122; and (b) identifying (i.e. detecting) a subject, which has a risk for developing metabolic syndrome and/or type-2 diabetes, wherein an increased amount of miR-122 as compared to the amount of miR-122 of a healthy reference population indicates a risk for developing metabolic syndrome and/or type-2 diabetes. Another aspect of the invention relates to a method for monitoring the therapeutic success during the treatment of metabolic syndrome and/or type-2 diabetes, wherein the method comprises (a) analyzing (i.e. determining/measuring/quantifying) in a first sample obtained from a test subject the amount of miR-122, wherein said first sample was obtained before or under treatment of the test subject with medication for metabolic syndrome and/or type-2 diabetes; (b) analyzing (i.e. determining/measuring/quantifying) in a second sample of said test subject the amount of miR-122, wherein said second sample was obtained under or after treatment of the test subject with medication for metabolic syndrome and/or type-2 diabetes; and (c) predicting the therapeutic success (i.e. detecting, whether therapeutic success exists), wherein a decreased amount of miR-122 in the second sample as compared to the first sample indicates therapeutic success.